If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The coat of arms shows a white horse (Saxon Steed) against a red background, which is an old symbol of the Saxon people. Legend has it that the horse was a symbol of the Saxon leader Widukind, albeit a black horse against a yellow background. The colours changed after the Christian baptism of Widukind. White and red are colours (besides black and gold) of the Holy Roman Empire symbolising Christ as the saviour, who is still shown with a red cross against a white background.
== Causes == Link rot can result for several reasons. A target web page may be removed. The server that hosts the target page could fail, be removed from service, or relocate to a new domain name. As far back as 1999, it was noted that with the amount of material that can be stored on a hard drive, "a single disk failure could be like the burning of the library at Alexandria." A domain name's registration may lapse or be transferred to another party. Some causes will result in the link failing to find any target and returning an error such as HTTP 404. Other causes will cause a link to target content other than that which was intended by the link's author. Other reasons for broken links include:
== Determining the RTD experimentally == Residence time distributions are measured by introducing a non-reactive tracer into the system at the inlet. Its input concentration is changed according to a known function and the output concentration measured. The tracer should not modify the physical characteristics of the fluid (equal density, equal viscosity) or the hydrodynamic conditions and it should be easily detectable. In general, the change in tracer concentration will either be a pulse or a step. Other functions are possible, but they require more calculations to deconvolute the RTD curve.
The matrix built from blocks with less than r% of similarity E.g., BLOSUM62 is the matrix built using sequences with less than 62% similarity (sequences with ≥ 62% identity were clustered together). Note: BLOSUM 62 is the default matrix for protein BLAST. Experimentation has shown that the BLOSUM-62 matrix is among the best for detecting most weak protein similarities. Several sets of BLOSUM matrices exist using different alignment databases, named with numbers. BLOSUM matrices with high numbers are designed for comparing closely related sequences, while those with low numbers are designed for comparing distant related sequences. For example, BLOSUM80 is used for closely related alignments, and BLOSUM45 is used for more distantly related alignments. The matrices were created by merging (clustering) all sequences that were more similar than a given percentage into one single sequence and then comparing those sequences (that were all more divergent than the given percentage value) only; thus reducing the contribution of closely related sequences. The percentage used was appended to the name, giving BLOSUM80 for example where sequences that were more than 80% identical were clustered.
Sources: en.wikipedia.org
== Structure == Hydrophobins are characterised by the presence of 8 conserved cysteine residues that form 4 disulphide bonds. They are able to reverse the wettability of surfaces by spontaneous self-assembly of the monomeric proteins into amphipathic monolayers at hydrophobic:hydrophilic surfaces. Despite this common feature, hydrophobins are subdivided into two classes based on differences on their monomeric structure, such as the spacing between the cysteine residues, and based on the different physicochemical properties of the amphipathic monolayers they form. Extensive structural analyses of individual hydrophobins from the two classes have elucidated that the morphological and physical differences between the class I and class II polymer forms are the results of significant structural differences at the monomer-assembly level.
The company also announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital platform for diabetes management. In November 2024, Dexcom announced a "strategic partnership" and data exchange with Oura.
=== Platelet disorders === Platelet disorders are either congenital or acquired. Examples of congenital platelet disorders are Glanzmann's thrombasthenia, Bernard–Soulier syndrome (abnormal glycoprotein Ib-IX-V complex), gray platelet syndrome (deficient alpha granules), and delta storage pool deficiency (deficient dense granules). Most are rare. They predispose to hemorrhage. Von Willebrand disease is due to deficiency or abnormal function of von Willebrand factor, and leads to a similar bleeding pattern; its milder forms are relatively common. Decreased platelet numbers (thrombocytopenia) is due to insufficient production (e.g., myelodysplastic syndrome or other bone marrow disorders), destruction by the immune system (immune thrombocytopenic purpura), or consumption (e.g., thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, paroxysmal nocturnal hemoglobinuria, disseminated intravascular coagulation, heparin-induced thrombocytopenia). An increase in platelet count is called thrombocytosis, which may lead to formation of thromboembolisms; however, thrombocytosis may be associated with increased risk of either thrombosis or hemorrhage in patients with myeloproliferative neoplasm.
Many street-level harm-reduction strategies have succeeded in reducing HIV transmission in people who inject substances and sex-workers. HIV education, HIV testing, condom use, and safer-sex negotiation greatly decreases the risk of acquiring and transmitting HIV.
=== Synopsis === In the beginning, there was Winter only. Unable to bear the loneliness in a world devoid of other seasons, he chose to cut off part of his vital essence to generate a new season, to whom he gave the name of "Spring". At the Mother Earth's wish, Winter again cut off his vital essence to give birth to Summer and Autumn, thus beginning the cycle of the four seasons. The Four Seasons visited every single corner of the world to perpetuate the cycle, until one day they decided to entrust this mission to Mother Earth's creatures, but none were capable of fulfilling the task. The Four Seasons fell into despair at having failed in their desired goal, until mankind made its appearance, willing to perform their duty in exchange for peace, prosperity and stability in its lands. The four deites of the seasons thus granted their powers to a small group of humans, who, over the centuries, have come to be known as the Agents of the Four Seasons.
Sources: en.wikipedia.org
=== Deleterious === Deleterious outcomes represent the majority of nonsense mutations and are the most common outcome that is observed naturally. Deleterious nonsense mutations decrease the overall fitness and reproductive success of the organism. For example, a nonsense mutation occurring in a gene encoding a protein can cause structural or functional defects in the protein that disrupt cellular biology. Depending on the significance of the functions of this protein, this disruption could be detrimental to the fitness and survival of that organism.
Lawrencium is a synthetic chemical element; it has symbol Lr (formerly Lw) and atomic number 103. It is named after Ernest Lawrence, inventor of the cyclotron, a device used to discover many artificial radioactive elements. A radioactive metal, lawrencium is the eleventh transuranium element, the third transfermium, and the last member of the actinide series. Like all elements with atomic numbers over 100, lawrencium can only be produced in particle accelerators by bombarding lighter elements with charged particles. Fourteen isotopes of lawrencium are known; the most stable is 266Lr with half-life 11 hours, but the shorter-lived 260Lr (half-life 2.7 minutes) is most commonly used in chemistry because it can be produced on a larger scale. Chemistry experiments confirm that lawrencium behaves as a heavier homolog to lutetium in the periodic table, and is trivalent. It could thus also be classified as the first of the 7th-period transition metals. Its electron configuration is anomalous for its position in the periodic table, having an s2p configuration instead of the s2d configuration of its homolog lutetium. However, this does not appear to affect lawrencium's chemistry. In the 1950s, 1960s, and 1970s, many claims of synthesis of element 103 of varying quality were made by laboratories in the Soviet Union and the United States. The priority of the discovery and therefore the name of the element was disputed between Soviet and American scientists.
This is a list of prices of chemical elements. Listed here are mainly average market prices for bulk trade of commodities. Data on elements' abundance in Earth's crust is added for comparison. As of 2025, the most expensive non-synthetic element by mass is rhodium, and by volume, iridium. It is followed by rhodium, caesium, iridium and palladium by mass and iridium, gold and platinum by volume. Carbon in the form of diamond can be more expensive than rhodium. Per-kilogram prices of some synthetic radioisotopes range to trillions of dollars. While the difficulty of obtaining macroscopic samples of synthetic elements in part explains their high value, there has been interest in converting base metals to gold (chrysopoeia) since ancient times, but only deeper understanding of nuclear physics has allowed the actual production of a tiny amount of gold from other elements for research purposes as demonstrated by Glenn Seaborg. However, both this and other routes of synthesis of precious metals via nuclear reactions is orders of magnitude removed from economic viability. Chlorine, sulfur and carbon (as coal) are cheapest by mass. Hydrogen, nitrogen, oxygen and chlorine are cheapest by volume at atmospheric pressure. When there is no public data on the element in its pure form, price of a compound is used, per mass of element contained. This implicitly puts the value of compounds' other constituents, and the cost of extraction of the element, at zero. For elements whose radiological properties are important, individual isotopes and isomers are listed.
The Mareth Line constituted one of two fronts in the Tunisia Campaign, the second being to the north-west, where the British First Army and American II Corps, firmly established in formerly Vichy-held Morocco and Algeria following Operation Torch in November 1942, were gradually pushing the Axis forces under Hans-Jürgen von Arnim back towards Tunis. After von Arnim won a decisive victory over the Americans at the Battle of Sidi Bou Zid in mid-February 1943, destroying over 100 US tanks, the Eighteenth Army Group was formed under the British General Harold Alexander to co-ordinate the actions of the Allied forces on both Tunisian fronts. The Eighth Army under Montgomery spent February at Medinine in south-eastern Tunisia. Expecting an imminent attack by the Axis, the Eighth Army mustered every anti-tank gun it could from Egypt and Libya. The 102nd (Northumberland Hussars) Anti-Tank Regiment, including the Rhodesian Anti-Tank Battery under Major Savory, duly advanced west from Benghazi and reached the front on 5 March 1943. The Germans and Italians assaulted Medinine the next day, but failed to make much progress and abandoned their attack by the evening. The Rhodesian gunners, held in reserve, did not take part in the engagement but were attacked from the air. The Rhodesians of the KRRC, now under the 7th Motor Brigade, moved up from Libya during early March. No. 237 (Rhodesia) Squadron, which had spent 1942 and the first months of 1943 in Iran and Iraq, returned to North Africa the same month, with the future Prime Minister Ian Smith in its ranks as a Hurricane pilot.
Neuroimaging studies have observed that fibromyalgia patients have increased grey matter in the right postcentral gyrus and left angular gyrus, and decreased grey matter in the right cingulate gyrus, right paracingulate gyrus, left cerebellum, and left gyrus rectus. These regions are associated with affective and cognitive functions and with motor adaptations to pain processing. Other studies have documented decreased grey matter of the default mode network in people with fibromyalgia. These deficits are associated with pain processing. According to a 2024 review article the evidence for central sensitization as an underlying mechanism in chronic pain conditions such as fibromyalgia has significant limitations, such as failing to demonstrate causality, and the use of measures described as measuring central sensitization which do not measure it as a neurophysiological phenomenon, leading to circular reasoning.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.